Fate Therapeutics, Inc. FATE · Stock Open Fate Therapeutics, Inc. in new tab
Fate Therapeutics, Inc. Analysis (FATE)
Is Fate Therapeutics, Inc. a good investment? Fate Therapeutics, Inc. (FATE) is currently trading at 2.50 USD. Market analysts have a consensus price target of 5.41 USD. This suggests a potential upside from current levels.
Earnings Schedule: Fate Therapeutics, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -0.99.
Investor FAQ
Does Fate Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Fate Therapeutics, Inc.?
Fate Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -1.09.
Company Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Community Discussion